Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistDynamic Blending Specialists, Inc., a drug manufacturer of OTC topical analgesic and oral care products, failed to conduct identity testing of drug components and did not validate or establish the reliability of component supplier test analyses, violating Current Good Manufacturing Practice (CGMP) regulations. The FDA's December 2024 inspection at their Vineyard, Utah facility identified these significant violations that rendered their drug products adulterated and introduced unapproved new drugs into interstate commerce. The company's manufacturing methods, facilities, and controls did not conform to CGMP requirements under 21 CFR parts 210 and 211, resulting in violations of the Federal Food, Drug, and Cosmetic Act.